Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer
Latest Information Update: 07 Oct 2022
At a glance
- Drugs Vincristine (Primary)
- Indications Acute myeloid leukaemia; Brain cancer; Ewing's sarcoma; Germ cell and embryonal neoplasms; Germ cell cancer; Glioma; Haematological malignancies; Hepatic tumours; Hodgkin's disease; Neuroblastoma; Non-Hodgkin's lymphoma; Osteosarcoma; Precursor cell lymphoblastic leukaemia-lymphoma; Rhabdomyosarcoma; Soft tissue sarcoma; Solid tumours; Wilms' tumour
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Spectrum Pharmaceuticals
- 26 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 26 May 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 28 Mar 2014 Planned End Date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.